The U.S. Food and Drug Administration has approved the first generic version of Roche’s flu treatment Tamiflu, marking another step in expanding access to lower-cost antiviral medicines for influenza.
The approval covers generic oseltamivir phosphate, which is used to treat and help prevent influenza, and comes after the agency prioritized review of the first generic application.
The move is expected to increase competition in the antiviral market and make flu treatment more affordable for patients, especially during seasonal outbreaks.
Tamiflu has long been one of Roche’s best-known flu medicines, and the approval of a generic version opens the door for broader access across the U.S. market.
The FDA considers the first generic approvals important to public health because they help bring down drug costs and improve the availability of essential medicines.
Roche’s flu drug remains one of the most widely recognized treatments for influenza, and the first generic approval is likely to intensify competition in this segment.
